Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Grassley Considering Hearings On Safety Of Sanofi-Aventis’ Ketek

This article was originally published in The Pink Sheet Daily

Executive Summary

The threat follows a meeting with FDA officials that the Finance Committee Chairman found unsatisfactory due to the absence of a line investigator involved with the agency’s scrutiny of the drug.

You may also be interested in...



Sanofi’s Ketek Gets December Advisory Committee Review

Two-day meeting expected to focus on safety issues related to the antibiotic, which has been associated with liver injury.

Sanofi’s Ketek Gets December Advisory Committee Review

Two-day meeting expected to focus on safety issues related to the antibiotic, which has been associated with liver injury.

Ketek Risk Cannot Be Distinguished From Class, FDA Says

Labeling for Sanofi-Aventis’ macrolide antibiotic telithromycin increases warnings about liver toxicity and myasthenia gravis.

Related Content

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel